Search for: "BOARD OF DIRECTORS OF ELI LILLY AND COMPANY"
Results 21 - 40
of 42
Sorted by Relevance
|
Sort by Date
18 Sep 2011, 5:57 pm
Eli Lilly and Co. spent the most on speakers, $61.5 million, and had about half the sales of Pfizer. [read post]
15 Jun 2007, 9:09 am
Drugmaker Eli Lilly's proxy specifies that CEO Sidney Taurel only used the company jet for personal travel to and from outside board meetings. [read post]
15 Apr 2021, 9:57 am
Samsung, Eli Lilly v. [read post]
23 May 2008, 9:20 am
The resolution, which won 48.8 percent support at Eli Lilly in 2007, received slightly more support--49.3 percent--at the firm this year. [read post]
28 Mar 2008, 7:25 am
Diversity The number of resolutions asking companies to increase efforts to diversify their boards has been shrinking. [read post]
20 May 2012, 1:11 pm
On the face of it, Plavix's patent expiry may have arguably paved the way for Eli Lilly & Co's and AstraZeneca's own blood-thinning drugs, Effient and Brilinta respectively, to gain more market share but the expiry of the patent does not mean that increasing the market share of their competitor drugs will be easy. [read post]
24 Mar 2011, 4:40 pm
He asked COSO to consider including it in the updated framework.Noting the Sarbanes-Oxley Sec. 407 requirement that companies disclose if they have a financial expert on the audit committee, SAG member, and Eli Lilly & Company Chief Accounting Officer, Arnold Hanish said that there is a need to beef up financial experts on boards. [read post]
29 Mar 2011, 12:33 pm
Eli Lilly & Co., 736 F.Supp.2d 219, 222-23 (D.D.C. 2010); White v. [read post]
9 Mar 2020, 1:21 pm
Companies are responsible for both express and implied claims. [read post]
7 Dec 2014, 3:29 pm
Among the significant –- but, really, very-well indexed –- number of issues, the decision delves into novelty, inventive step, insufficiency by excessive claim breadth, added matter, and claim construction in light of the influential Actavis v Eli Lilly, another Arnoldian decision that the very same judge clarifies further in this ruling. [read post]
24 Jul 2011, 9:44 am
Human Genome Sciences Inc v Eli Lilly and Company, heard 18 – 20 July 2011. [read post]
13 Jun 2012, 7:24 am
If whistleblowers’ compensation is measured against their contribution to the common good and compared to let’s say, the Hollywood movie star du jour or the corporate executive that, after a losing year, convinces the Board of Directors (wink nod) to provide a pay package worth tens of millions, whistleblowers are a bargain. [read post]
23 Dec 2007, 8:00 pm
: (IPKat),Amazon gift ordering patent revoked by the EPO: (OUT-LAW), (IP Law360)Legal protection for databases: case report on dispute between the British Horseracing Board and William Hill: (OUT-LAW),Court of First Instance rejects Enercon's appeal to register a football-shaped wind turbine as a Community trade mark: (Mondaq.com),More on registrability of Tarzan's yell as a trade mark at OHIM: (OUT-LAW), (more from OUT-LAW),Gateway Inc. cannot… [read post]
8 Feb 2008, 7:00 pm
– Facebook’s contractual rights to users’ photos problematic: (Spicy IP)PharmaEuropean Commission probes pharmaceutical sector: (Philip Brooks),WHO Board sets course on IP, avian flu, tighter publication policy: (Intellectual Property Watch),India: The Competition Act, patents and over hyped drugs: (Part I - Spicy IP), (Part II – Spicy IP), (Part III – Spicy IP),Ignoring not the solution … [read post]
5 Jul 2008, 11:05 am
: (IP tango), China: Pfizer loses trade mark action against Jaingsu Lianhuan Pharmaceutical Co over 3D mark: (Rouse & Co International), India: More patents for new forms issued to generics: (Patent Circle), India: Gauri Kamath on drug ‘differential pricing’ in India: (Spicy IP), Mexico: Revised health supplies regulations promise changes for generics: (International Law Office), US: World drug pricing crisis: Congressmen criticise US Trade Representative over Special 301… [read post]
9 Aug 2008, 1:50 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: The end of William Patry’s blog: (Patry Copyright Blog), (Excess Copyright), (Patently-O), (Chicago IP Litigation Blog), (Michael Geist), (The Fire of Genius), (Techdirt), (Patry Copyright Blog), Kitchin J clarifies scope of biotech patents, in particular gene sequence patents: Eli Lilly & Co v Human Genome… [read post]
6 Mar 2020, 3:00 am
National/Federal Biden Claims 9 Super Tuesday Victories, Including Texas AP News – Steve Peoples and Will Weissert | Published: 3/4/2020 A resurgent Joe Biden scored victories from Texas to Massachusetts on Super Tuesday, revitalizing a presidential bid that was teetering on the edge of disaster just days earlier. [read post]
9 May 2008, 10:30 pm
: (Afro-IP), (Managing Intellectual Property), Rwanda: Four years after AIDS drugs bill passed, first low cost meds may head to Rwanda: (GenericsWeb), US: Abbott’s first quarter lobbying tab hits $880,000: (Patent Docs), US: House Bill would expand federal drug pedigree requirements and preempt state requirements: (FDA Law Blog), US: Purchasing Canadian drugs and patent infringement: Litecubes decision: (Patently-O), US: Neuralstem seeks to reopen stayed patent case… [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay generics in 2007:… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying… [read post]
